Editorials

Is a Patient Questionnaire Without a Joint Examination as Undesirable as a Joint Examination Without a Patient Questionnaire?
T. Pincus, K.A. Gibson, J-M.M. Berthelot ................. 619

Resolution of Proteinuria in Lupus Nephritis: Hurry Up and Wait
J.M. Bargman, C. Avila-Casado ................................. 622

Further Evidence for Influenza and Pneumococcal Vaccination in Patients Treated with Disease Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents M.C. Kapetanovic .................................. 626

Articles

Subcutaneous Abatacept for the Treatment of RA: Longterm Data from the ACQUIRE Trial M.C. Genovese, C. Pacheco Tena, A. Covarrubias, et al .................................. 629

Is Tightly Controlled Disease Activity Possible with Online Patient-reported Outcomes?
M.J. Walter, S.H. Mohd Din, J.M. Hazes, E. Lesaffre, P.J. Barendregt, J.J. Luime ........................................ 640

Vaccine Responses in Patients with RA Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial

Retinol-binding Protein 4 in RA-related Insulin Resistance and β-cell Function
I. Ferraz-Amaro, M.A. González-Gay, F. Diaz-González ..658

Abatacept Reduces Levels of Switched Memory B Cells, Autoantibodies, and Immunoglobulins in Patients with RA
M. Scarsi, L. Paolini, D. Ricotta, et al .......................... 666

Systemic Autoimmune Rheumatic Disease Prevalence in Canada: Updated Analyses Across 7 Provinces
L. Broten, J.A. Aviña-Zubieta, D. Lacaille, et al .................. 673

Mortality and Cardiovascular Burden of SLE in a US Population-based Cohort
C.M. Bartels, K.A. Buhr, J.W. Goldberg, et al .................. 680

Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment

Frailty Index to Measure Health Status in People with SSC
M.R. Rockwood, E. MacDonald, E. Sutton, K. Rockwood, Canadian Scleroderma Research Group, M. Baron ........ 698

Impaired Left Ventricular Apical Rotation is Associated with Disease Activity of PsA Q. Shang, L-S. Tam, J-E. Sanderson, A.P-W. Lee, E.K-M. Li, C-M. Yu ............... 706

Hemostatic and Fibrinolytic Changes Are Related to Inflammatory Conditions in Patients with PsA — Effect of Different Treatments M.N. Di Minno, R. Peluso, A. Di Minno, P. Ambrosino, R. Scarpa, and the CaRRDs Study Group ....................... 714

Factors Associated with Major CV Events in Patients with Systemic Necrotizing Vasculitides: Results of a Longterm Followup Study B. Terrier, G. Chironi, C. Pagnoux, et al, for the French Vasculitis Study Group ....................... 723

Joint Involvement in Patients with Early PMR Using High-resolution Ultrasound and Its Contribution to the EULAR/ACR 2012 Classification Criteria for PMR
S. Weigand, B. Ehrenstein, M. Fleck, W. Hartung .......... 730

Colchicine in Behçet Syndrome: A Longterm Survey of Patients in a Controlled Trial
V. Hamuryudan, G. Hatemi, K. Tascilar, et al ............... 735

Treatment of Asymptomatic Hyperuricemia and Prevention of Vascular Disease: A Decision Analytic Approach
R. Akkineni, S. Tapp, A.N.A. Tosteson, et al ................. 739

Joint Effects of Alcohol Consumption and ABCG2 Q141K on Chronic Tophaceous Gout Risk

Pediatric Rheumatology

Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic JIA in Japan
S. Yokota, T. Imagawa, M. Mori, et al .......................... 759

Transitioning Youth with Rheumatic Conditions: Perspectives of Pediatric Rheumatology Providers in the United States and Canada
P. Chira, T. Ronis, S. Ardoin, P. White .......................... 768
Images in Rheumatology
Multicentric Reticulohistiocytosis Can Mimic RA
M.L. Krause, J.S. Lehman, K.J. Warrington .......... 780

OMERACT
Disease-specific Outcomes II
Development of a Disease Activity and Responder Index
for PsA — Report of the PsA Module at OMERACT 11
L.C. Coates, O. FitzGerald, P.J. Mease, et al .......... 782
Reconciling Healthcare Professional and Patient
Perspectives in the Development of Disease Activity and
Response Criteria in Connective Tissue Disease–related
Interstitial Lung Diseases L.A. Saketkoo, S. Mittoo,
S. Frankel, et al, and the OMERACT Connective Tissue
Disease–Interstitial Lung Diseases Working Group .... 792
Establishing a Core Domain Set to Measure RA Flares:
Report of the OMERACT 11 RA Flare Workshop
V.P. Bykerk, E. Lie, S.J. Bartlett, et al ................. 799
Report from the OMERACT Hand OA Special Interest
Group: Advances and Future Research Priorities
M. Kloppenburg, P. Bøyesen, W. Smeets, et al ........ 810
Polymyalgia Rheumatica (PMR) Special Interest Group
at OMERACT 11: Outcomes of Importance for
Patients with PMR
Meetings in Rheumatology .............................. x